Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR2 positive |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04483505 | Phase I | Fulvestrant + Palbociclib + Rogaratinib | Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST) | Completed | ESP | 0 |
NCT06680622 | Phase II | Bemarituzumab + Paclitaxel + Ramucirumab Bemarituzumab + Trifluridine-tipiracil hydrochloride Bemarituzumab + Irinotecan | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Not yet recruiting | DEU | 0 |
NCT02368951 | Phase I | Aprutumab ixadotin | Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) | Terminated | USA | 2 |